Saturday, May 14th & Sunday May 15th,
2005 - Prior to the ISPOR 10th
Annual International Meeting
For
short course descriptions and faculty information go to:
· Saturday, May 14th:
http://www.ispor.org/meetings/washington0505/sc14.asp
· Sunday, May 15th:
http://www.ispor.org/meetings/washington0505/sc15.asp
Pharmacoeconomics Courses:
· Pharmacoeconomics for
Decision-makers – Saturday Full Day Course (8:00am-5:00pm)
· Elements of
Pharmaceutical Pricing – Sunday Morning Course (8:00am-12:00pm)
Clinical Assessment Courses:
· Retrospective Database
Analysis: Econometric Methods – Sunday Full Day Course (8:00am-5:00pm)
· Meta-Analysis and
Systematic Literature Review – Sunday Morning Course (8:00am-12:00pm)
Modeling Courses:
· Bayesian Analysis:
Overview – Saturday Morning Course (8:00am-12:00pm)
· Bayesian Analysis:
Applications – Saturday Afternoon Course (1:00pm-5:00pm)
· Modeling: Structure
& Design of Model – Sunday Full Day Course (8:00am-5:00pm)
· Discrete Event
Simulation for Economic Analyses - Sunday Afternoon Course (1:00pm-5:00pm)
· Introduction to Decision Analysis – Saturday Afternoon
Course (1:00pm-5:00pm)
Quality of Life/Patient-reported Outcomes Courses:
· Introduction to
Quality of Life/Patient-Reported Outcomes – Saturday Afternoon Course
(1:00pm-5:00pm)
· Old and New Utility
Measures in Health Economics and Outcomes Research – Sunday Morning Course
(8:00am-12:00pm)
· Advanced Quantitative
Methods for Quality of Life/Patient-reported Outcomes Research – Sunday Afternoon
Course (1:00pm-5:00pm)
Economic Analysis Courses:
· Financial Impact /
Cost of Illness – Saturday Afternoon Course (1:00pm-5:00pm)
· Cost Estimation:
Finding and Extracting Cost Data – Sunday Morning Course (8:00am-12:00pm)
· Statistical
Considerations in Economic Evaluations – Sunday Afternoon Course
(1:00pm-5:00pm)
ISPOR Distance Learning Program Modules
http://www.ispor.org/distancelearning/index.asp
The following module topics are currently available (total
of 40 modules):
·
Pharmacoeconomics
·
Pharmacoeconomic
Evaluations & Methods
·
Cost-Effectiveness
Analysis
·
Cost-Benefit
Analysis
·
Cost-Utility
Analysis
·
Patient-Reported
Outcomes (Utilities, Health-Related Quality Of Life, Treatment Satisfaction,
Treatment Adherence, Patient Preferences)
·
Study Design in
Pharmacoeconomics
·
Guidelines
and Reference Standards
·
Pharmacoeconomics
in Drug Development, Reimbursement and Marketing
- STUDENT NEWS
Top
Visit ISPOR Internship- Professional Recruitment Assistance Program
(I-PRAP)
http://www.ispor.org/iprap/index.asp
STUDENTS have the opportunity to search for
internship positions available and post their CVs/resumes for employers to
view. Post your CV today!
EMPLOYERS have the opportunity to access CVs/resumes from interested
students.
For more details on the ISPOR
Student Network, please visit:
http://www.ispor.org/student/student_index.asp
- ISPOR SPECIAL INTEREST GROUPS (SIG)
Top
VALUE-BASED REIMBURSEMENT SIG
Value-based Reimbursement SIG Open Meeting: Tuesday, May 17,
5:00 – 6:00 PM
The mission, working
groups, leadership and future activities of the SIG will be presented.
Open to all meeting participants.
Speaker: Diane L. Simison PhD, Chair, Value-based Reimbursement SIG and Executive Director, MEDTAP
Institute at UBC, Center for Pricing and Reimbursement.
**NEW** Working Group Chairs:
· Evidence and Payer Decision-making
Working Group
Nancy Risebrough Senior Associate, HOPE Research
Centre, Toronto, Ontario,
Michael Halpern MD, MPH, PhD, Chief Scientist, Exponent, Alexandria, VA
· Global Reimbursement Strategies
Working Group
Geoffrey Wilson DPhil, BSc, MSc, PhD, Managing Director, ValuemoniX,
Penn, UK
Jennifer Stephens PharmD, Senior Clinical Consultant, PharMerit,
Bethesda, MD USA
· Global Reimbursement Trends Working
Group
Stefan Holmstrom BSc, MSc,
Manager, Strategic Pricing & Reimbursement, Allergan, Biot, France
Kevin Mayo PhD, Head, Global Strategic Pricing & Health Economics (NS &
ID), Novartis Pharmaceuticals, Basel, Switzerland
· Reimbursement Literature Working
Group
Paul Trueman MA, Sales & Marketing Director, York Health Economics
Consortium, University of York, Heslington, York, UK
Parthiv Mahadevia MD,
MPH, Associate Director, Payment and
Coverage Group, Amgen, Inc., Washington, DC, USA
· Payer-oriented Evidence Guidelines
Working Group
James Mackay MD,
Medical Director, Providence Health Plans, Beaverton, OR, USA
Joseph Singer MD, Vice President, HealthCore, Inc, Wilmington, DE, USA
For more
details on this SIG, please visit:
http://www.ispor.org/sigs/reimbursement.asp
HEALTH TECHNOLOGY ASSESSMENT SIG
Health Technology Assessment SIG Open Meeting on Monday, May 16 at 5:30 PM
The mission, working
groups, leadership and future activities of the SIG will be presented.
Open to all meeting participants.
Speaker: Frank Papatheofanis MD, MPH, PhD,
Chair, Health
Technology Assessment SIG and
Director of the Advanced
Medical Technology Assessment & Policy Program and
Associate Professor of Radiology and Economics
University of California at San Diego
**NEW** Working Group Chairs
· HTA Methodology Working Group
Francis Pang BSc, MSc, PhD, Head of Health Economics, Abbott Laboratories, Maidenhead, UK
Alan Barkun MD, Director, Division of Gastroenterology, McGill University
Health Centre, Montreal General Hospital,
Montreal, QC, Canada
· HTA in Reimbursement Economics
Working Group
Jalpa Doshi PhD,
Health Services Research Scientist, General Internal Medicine, University of
Pennsylvania, Philadelphia, PA USA
Bonnie Handke RN, Sr. Reimbursement Manager, Medtronic,
Minneapolis, MN, USA
· Applied HTA Working Group
Uwe Siebert MD, MPH, MSc, Director, Cardiovascular Research Program, MGH Institute for Technology Assessment, Harvard Medical School, Boston, MA, USA
Philip Booth MS, Director of Health Technology Appraisal, Novartis
Pharmaceuticals, Frimley, Camberley, UK
· HTA to Support Marketing Initiatives
Working Group
Sheryl Szeinbach BS, MS, PhD, RPh, Professor, College of Pharmacy, Ohio State
University, Columbus, OH, USA
Noreen Sullivan BS, Vice President, Aequitas, San Diego, CA, USA
For more details on this SIG, please visit:
http://www.ispor.org/sigs/hta.asp
CLINICAL PRACTICE SIG
Clinical Practice SIG
Forum:
Tuesday May 17, 4:00– 5:00 PM, at the ISPOR 10th Annual International
Meeting.
Topic: Applying Pharmacoeconomic Principles in Clinical Practice . . .
Noble Enterprise or Pipe Dream?
and
the Value Proposition to Payers & Providers: Do Pharmacoeconomic Studies
Meet the Needs of Decision Makers?
Stakeholder perspectives (payer, hospital and individual provider) will be
presented and real-world examples of how outcomes research and pharmacoeconomic
principles are applied across different medical centers, in Pharmacy &
Therapeutics Committees and how patient outcomes can be used to develop practice
guidelines and evaluate treatment outcomes.
We will close with an audience discussion about restrictions
that currently prevent the widespread usage of outcomes research and
pharmacoeconomics in decision making along with suggested measures to take to
change the current situation.
Moderator: Ramon Bautista MD, MBA, Department of Neurology,
University of Florida HSC Jacksonville, FL, USA; Speakers:
F. Randy Vogenberg RPh, PhD, Senior Vice President & National
Practice Council Leader, Aon Consulting, Life Sciences Consulting Practice,
Providence, RI, USA; Sara Shull MBA, PharmD, Drug Policy and Economics
Pharmacist Specialist, Nebraska Health System Name, Omaha, NE, USA; Peter K.
Wong PhD, MBA, RPh Vice President, Clinical Effectiveness & PI, Good
Samaritan Hospital, Dayton, OH,USA.
Clinical Practice SIG Workshop: Monday, May 16, 2:00 – 3:00 PM
during the ISPOR 10th Annual International Meeting.
Topic: Standardized Reporting Format for Outcomes Research or Economic
Evaluation and a System to Measure the Strength of Evidence of Studies
Speakers: Peter K. Wong PhD, MBA, RPh, Vice President, Clinical
Effectiveness & PI, Good Samaritan Hospital, Dayton, OH, USA; Alan Bakst MBA,
PharmD, Director, Health Economics and Outcomes Research, TAP Pharmaceutical
Products Inc, Chicago, IL, USA; Alan Mutnick PharmD, Assistant Director
Clinical Practice, University of Virginia Health System, Charlottesville, VA,
USA.
For more details on this SIG, please visit:
http://www.ispor.org/sigs/cp.asp
PATIENT REGISTRY SIG
Patient Registry SIG Forum, Monday, May 17, 4:30 – 5:30 PM, at the ISPOR 10th
Annual International Meeting.
Topic: Patient Registries: Opportunity and Responsibility
Key issues will be discussed, including the industry’s role in sponsoring
post-approval registries that capture “real world” clinical, economic, and
humanistic data and other evaluations critical for a more accurate
characterization of how drugs and devices are utilized in actual medical
practice. In addition, the findings from the Patient Registry survey will
be presented and the Working Group Chairs will comment on issues involving
commercialization, safety surveillance, analytical methods, technology, and
global initiatives. The session will include an open forum to solicit
ISPOR member comments.
Moderator: Jeffrey
Trotter MM, President, Ovation Research Group, Highland Park, IL Speakers:
Melva T. Covington MPH, MBA, PhD, Team Leader, Global Health Outcomes
Eli Lilly and Company, Indianapolis, IN, USA; Mohan Bala PhD, Director,
Outcomes Research Centocor, Inc, Malvern, PA, USA: Peter Malamis MBA,
Vice-President & General Manager, Post-Marketing Business Unit, Scirex,
Horsham, PA, USA; Hugh Levaux PhD, CEO, Ninaza, San Mateo, CA,
USA; Leanne Larson MHA, Vice President, Strategy & Development,
Ovation Research Group, Highland Park, IL, USA.
For more details on this SIG, please visit:
http://www.ispor.org/sigs/patient_registr.asp
QUALITY OF LIFE SIG
Quality of Life SIG Forum: Tuesday, May 17, 4:00 – 5:00 PM
Topic: Health Status and Patient Reported
Outcomes / Quality of Life Measures in the ‘Real World'
Moderator: Pennifer Erickson PhD, Co-founder, O.L.G.A., State College,
PA, USA; Benefits of Using ‘Real World’ Quality of Life/Patient Reported
Outcomes, Speaker: Mary Cifaldi RPh, PhD Assistant Director,
Abbott Laboratories, Abbott Park, IL, USA; Challenges and Limitations of
‘Real World’ Quality of Life/Patient Reported Outcomes, Speaker:
Richard Chapman PhD, Director, Health Economics, ValueMedics Research, Alexandria,
VA, USA; Methods and Best Practices for ‘Real World’ Quality of Life/Patient
Reported Outcomes Studies, Speaker: Jamie Banks MS, Health
Outcomes Strategy Group, Boston, MA, USA; Next Steps for ISPOR, Speaker:
Andreas Pleil PhD, Director/Site Leader Worldwide Outcomes
Researchomics, Pfizer Incorporated, San Diego, CA, USA;
Quality of Life SIG Open Meeting: Tuesday, May 17 5:00 – 6:00 PM
The mission, working groups, leadership and future
activities of the SIG will be presented. Open to all meeting participants.
Speaker: Judith Barr PhD, Associate Professor, Northeastern University & Director,
National Education and Research Center for Outcomes Assessment, Boston, MA,
USA.
For more details on this SIG, please visit:
http://www.ispor.org/sigs/qol.asp
MEDICATION COMPLIANCE SIG
10th Annual International Meeting Activities:
Monday, May 16th at 4:30pm – 5:30pm – ALL WELCOME!
Three workshops will be presented:
W1 Methods for Medication Compliance Studies: An Overview of
the ISPOR Medication Compliance SIG Guidelines, Monday, May 16, 2:00 – 3:00 PM
W8 Medication Compliance (Adherence): issues and Definitions
Consensus Workshop 2005, 3:15 – 4:15 PM.
W15 Methods for Medication
Compliance Studies: The Importance of Statistical Distributions, Tuesday, May 17, 2005, 1:30 –
2:30 PM.
**NEW**Analyses Standards WG:
A draft checklist for Medication Compliance Studies Using
Retrospective Drug Utilization Data is available at
http://www.ispor.org/sigs/eval_checklistdraft.asp.
Please forward all comments to
medcompsig@ispor.org
For more details on this SIG, please visit:
http://www.ispor.org/sigs/medication.asp
RETROSPECTIVE DATABASE SIG
Retrospective Database SIG Forum: Tuesday, May 17, 4:00 – 5:00 PM
During this forum,
the development of the ISPOR Digest of International Databases for Pharmacoeconomics
and Outcomes Research will be presented.
Speakers: Carl Asche PhD, Co-Chair, Classification of
Databases Working Group & Associate Professor, University of Utah, Salt
Lake City, UT, USA; Gordon Cummins MS, Co-Chair Classification of
Databases Working Group & Vice President, Sales & Account Management,
HealthCore, Inc.
Retrospective
Database SIG OPEN MEETING: Tuesday, May 17 5:00PM
This Open Meeting is a continuation of the Retrospective Database
SIG Forum to provide an opportunity for attendees to comment on how to find
these database organizations and the right questions to ask for information
about the types of databases (questionnaire form).
Speakers: Carl Asche PhD, Co-Chair Classification of Databases Working Group &
Associate Professor, University of Utah, Salt Lake City, Utah; Gordon
Cummins MS, Co-Chair Classification of Databases Working Group &
Vice President, Sales & Account Management, HealthCore, Inc.
For more details on this SIG, please visit:
http://www.ispor.org/sigs/retrospective_db.asp
RISK MANAGEMENT SIG
The Risk Management SIG is presenting two workshops:
W7
BALANCING RISKS AND BENEFITS OF HEALTHCARE TREATMENTS IN THE 21ST
CENTURY, Monday, May 16, 2005, 2 – 3 PM.
The workshop will explore and comment on the areas of
risk/benefit assessment, offering interesting material on how to balance the
two. A fascinating and interactive group case study will be performed
following the presentation.
Speakers: Dennis Raisch (SIG Chair), VA Cooperative Studies Program, Albuquerque,
NM, USA; Larry Liu (Co-chair, Identification Working Group), Pfizer
Global Pharmaceuticals, New York, NY, USA; Paul Stang (Co-chair, Intervention/Implementation,
Communication Working Groups), Associates, Inc. and West Chester University,
Blue Bell, PA, USA; Ateequr Rahman (Co-chair, Communication Working
Group), Shenandoah University, Winchester, VA, USA; Anthony Lockett (Co-chair,
Intervention/Implementation Working Group), ICO, Leeds, W Yorkshire, UK; and Nicholas
Lipskiy (Co-chair, Identification Working Group), Surveillance Data Inc,
Plymouth Meeting, PA, USA.
W14 ISPOR MEMBER PERSPECTIVES: HOW DO INDIVIDUALS PERCEIVE RISKS AND
BENEFITS OF PHARMACEUTICALS IN COMPARISON WITH OTHER NON-MEDICAL ACTIVITIES
Monday, May 16, 2005, 3:15 – 4:15 PM.
This workshop will expose and analyze the results of a healthcare
survey given to ISPOR membership. Interesting findings include: US
v. non-US comparisons of risk assessment, the amount of effect that individual
side-effect experiences had on the perception of risk associated with other
pharmaceuticals, and much more!
Speakers: Dennis Raisch (SIG Chair), VA Cooperative Studies Program, Albuquerque,
NM, USA; Larry Liu (Co-chair, Identification Working Group), Pfizer
Global Pharmaceuticals, New York, NY, USA; Paul Stang (Co-chair, Intervention/Implementation,
Communication Working Groups), Associates, Inc. and West Chester University,
Blue Bell, PA, USA; Ateequr Rahman (Co-chair, Communication Working
Group), Shenandoah University, Winchester, VA, USA; Anthony Lockett (Co-chair,
Intervention/Implementation Working Group), ICO, Leeds, W Yorkshire, UK; and Nicholas
Lipskiy (Co-chair, Identification Working Group), Surveillance Data Inc,
Plymouth Meeting, PA, USA.
For more details on this SIG, please visit:
http://www.ispor.org/sigs/rm.asp
MANAGED CARE SIG
For more details, please visit:
http://www.ispor.org/sigs/mc_pbm.asp
Special
Interest Group membership is open to ALL ISPOR members. To JOIN any SIG:
http://www.ispor.org/sigs/joinsig.htm
- ISPOR BOARD, COMMITTEE, AND TASK FORCE ACTIVITIES
Top
AWARD COMMITTEE ACTIVITIES
2005 ISPOR AVEDIS DONABEDIAN
OUTCOMES RESEARCH LIFETIME ACHIEVEMENT AWARD RECIPIENT
The recipient of this year's award is Katherine N. Lohr,
PhD, MPhil, MA of RTI International, Durham NC, USA.
2005 ISPOR BERNIE O'BRIEN NEW INVESTIGATOR AWARD RECIPIENT
The first recipient of this new annual ISPOR award is Shelby
D. Reed, PhD, RPh, of Duke Clinical Research Institute, Raleigh, NC, USA.
2005 ISPOR RESEARCH EXCELLENCE AWARD
RECIPIENTS
The recipient of the 2005 ISPOR Research Excellence Award
for Methodology Excellence is Joshua Salomon PhD, Assistant Professor of
International Health, Harvard Center for Population and Development Studies, Cambridge, MA, USA, for his paper, "A Multi-Method Approach to Measuring Health-State
Valuations." Health Econ 2004;13:281-90.
The recipient of the 2005 ISPOR Research Excellence Award
for Practice Application Excellence is Sebastian Schneeweiss MD, ScD, Assistant
Professor of Medicine and Epidemiology, Harvard Medical School and Harvard
School of Public Health, Boston, MA, USA, for his paper, "Clinical and
Economic Consequences of a Formulary Restriction of Nebulized Respiratory Drugs
in Adults: Direct Comparison of Randomized and Observational Evaluations."
Br Med J 2004;328:560-4.
The recipients of these and other ISPOR Awards will be
presented their award at the ISPOR 10th Annual International Meeting
in Washington, DC on May 17, 2005.
For more details, please visit:
http://www.ispor.org/awards/index_.asp
ISPOR TASK FORCE: USING "REAL WORLD"
DATA IN COVERAGE AND REIMBURSEMENT DECISIONS
The Real World Task Force Working Groups (Evidence Hierarchy, Clinical Outcomes,
Economic Outcomes, and Patient Reported Outcomes) continue to put
forth great efforts in their mission to: 1) identify the issues (related to
using and interpreting "real world" data); 2) develop a best
practices document (a white paper) with a collaborative submission to Value
in Health tentatively scheduled for July 2005; and 3) develop an action
plan for outreach and communication.
For more details, including a draft outline of this final
paper, and a list of core group members, go to:
http://www.ispor.org/workpaper/real_world_data.asp
NOMINATIONS COMMITTEE
**NEW** 2005 ISPOR Board of Directors Election Results
